Sugi Predict

Sugi Predict / Compounds / SCHEMBL2392418

SCHEMBL2392418

SCHEMBL2392418

CN(C[C@H]1CC[C@H](NC(=O)OC(C)(C)C)CC1)c1ccc(Br)c(F)n1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 7/20 0.41
▸ KDM1A O60341 2/20 0.39
▸ MAOB P27338 1/20 0.39
▸ DRD3 P35462 1/20 0.38
▸ CKS1B P61024 1/20 0.38
▸ SKP1 P63208 1/20 0.38
▸ SKP2 Q13309 1/20 0.38
▸ JAK1 P23458 2/20 0.36
▸ KAT8 Q9H7Z6 1/20 0.36
▸ JAK2 O60674 1/20 0.35
▸ PBK Q96KB5 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ MERTK Q12866 1/20 0.35
▸ SUV39H2 Q9H5I1 1/20 0.35
▸ KCNA3 P22001 1/20 0.35
▸ CACNA1H O95180 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2392421 1.00 DRD2 (0.41) DRD2KDM1AMAOBDRD3CKS1B
SCHEMBL15342805 1.00 DRD2 (0.41) DRD2KDM1AMAOBDRD3CKS1B
SCHEMBL2392098 0.82 DRD2 (0.43) DRD2KDM1AMAOBDRD3CKS1B
SCHEMBL2392095 0.82 DRD2 (0.43) DRD2KDM1AMAOBDRD3CKS1B
SCHEMBL15342766 0.82 DRD2 (0.43) DRD2KDM1AMAOBDRD3CKS1B
SCHEMBL15342785 0.81 DRD2 (0.42) DRD2KDM1AMAOBDRD3KAT8
SCHEMBL2397159 0.81 DRD2 (0.42) DRD2KDM1AMAOBDRD3KAT8
SCHEMBL2397153 0.81 DRD2 (0.42) DRD2KDM1AMAOBDRD3KAT8
SCHEMBL15342806 0.81 DRD2 (0.43) DRD2KDM1AMAOBDRD3CKS1B
SCHEMBL2392284 0.81 DRD2 (0.41) DRD2KDM1AMAOBDRD3CKS1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051279-B2 Substituted isoquinolinones and quinazolinones NOVARTIS AG (CH) 2015-06-09 — — US disclosed
EP-2516009-B1 SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES NOVARTIS AG (CH) 2014-09-24 — — EP disclosed
US-20130281473-A1 SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES NOVARTIS AG (CH) 2013-10-24 — — US disclosed
US-8440693-B2 Substituted isoquinolinones and quinazolinones NOVARTIS AG (CH) 2013-05-14 — — US disclosed
US-8440693-B2 Substituted isoquinolinones and quinazolinones NOVARTIS AG (CH) 2013-05-14 — — US disclosed
US-8440693-B2 Substituted isoquinolinones and quinazolinones NOVARTIS AG (CH) 2013-05-14 — — US disclosed
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones NOVARTIS AG (CH) 2011-09-22 — — US disclosed
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones NOVARTIS AG (CH) 2011-09-22 — — US disclosed
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones NOVARTIS AG (CH) 2011-09-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones MDM4, MDM2, TP53 DRD2 1974/4885KDM1A 1216/4885MAOB 1800/4885
US-20130281473-A1 SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES MDM4, MDM2, TP53 DRD2 1974/4885KDM1A 1216/4885MAOB 1800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.